MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer [ChIP-seq]
ChIP-seq / ATAC-seq (genome binding and open chromatin) · mouse · 3 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Mus musculus (mouse)
- Samples
- 3 samples
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate CancerCancer research communications · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE271328_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1130939 and SRA study SRP517607. Searching any of these in the dataset finder brings you back here.
The sample list for this study is not cached yet. Press Load samples and it will be fetched from NCBI.
+ 3 more — browse all 3 samples with per-sample file links →
- GSE271327 MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer [ATAC-seq] 3 samples shares rb1-loss, mybl2, cdk2, neuroendocrine, vulnerability, therapeutic, plasticity, identifies
- GSE271412 MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer 8 samples shares rb1-loss, mybl2, cdk2, neuroendocrine, vulnerability, therapeutic, plasticity, identifies
- GSE280263 Actin Dysregulation Induces Neuroendocrine 1 Plasticity and 2 Immune Evasion: A Vulnerability of Small Cell Lung Cancer 2 samples shares neuroendocrine, vulnerability, plasticity
- GSE271066 A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer. 44 samples shares neuroendocrine, identifies
- GSE271053 A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer [RNA-Seq] 43 samples shares neuroendocrine, identifies
- GSE89664 MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition 20 samples shares neuroendocrine, vulnerability
- GSE279200 Basal cell of origin resolves neuroendocrine-tuft lineage plasticity in cancer [Single cell RNA-seq] 14 samples shares neuroendocrine, plasticity
- GSE289248 Crosstalk between the polycomb repressive complex 2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity [RNA-Seq] 2 samples shares neuroendocrine, plasticity
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.